SYNTHESIS OF THE COMPLETE GLYCOTETRAPEPTIDE CORE OF STRUCTURALLY VARIANT MYCOBACTERIUM FORTUITUM GLYCOPEPTIDOLIPID

M K Gurjar and U K Saha
Indian Institute of Chemical Technology, Hyderabad 500 007, India

(Received in USA 16 November 1992)

Abstract: The synthesis of a glycotetrapeptide present in the novel structurally variant glycopeptidolipid of <u>Mycobacterium</u> fortuitum has been described by employing Schmidt's trichloroacetimidate approach for the crucial <u>O</u>-glycosylation reactions.

Mycobacterium (M.) fortuitum is one of the major causes of human disease among the class of mycobacterial infections. It is considered as an etiological agent of skin, soft tissue, post-surgical and pulmonary human infections. The bacteria does not respond to antituber-culotic drugs while activity against antimicrobial agents highly depends upon species and subvariant, which need precise identification of bacterial species for chemotherapy. The serologically differentiated glycopeptidolipids (C-mycosides) of mycobacteria contain a typical glycotetrapeptide core common to all C-mycosides. The hydroxyl group of D-allo-threonine is attached to an antigenic and structurally variable oligosaccharide chain which invariably contains a characteristic terminal disaccharide α -L-RhaP(1 + 3)-6-deoxy-L-talose unit. Recently variations in the structure of glycopeptidolipids were reported particularly for M. fortuitum and M. xenopi. Although in M. fortuitum glycopeptidolipid (1) the peptide core remained unaltered, the oligosaccharide chain was now attached to the terminal L-alinilol residue and did not contain the characteristic α -L-RhaP-(1 + 3)-6-deoxy-L-talose, such features unknown in mycobacterium genus. In addition, the hydroxyl group of D-allo-threonine was linked to 3-O-methyl- α -L-rhamnopyranose unit instead of 6-deoxy-L-talose.

The oligosaccharides obtained from \underline{M} . fortuitum have been identified as 3,4-di- \underline{O} -Me- α -L-RhaP- $(1 \rightarrow 2)$ -3,4-di- \underline{O} -Me- α -L-RhaP (mycoside II). Inspite of several developments in the field of glycopeptide synthesis, practically very little work has been carried out towards mycobacterial glycopeptides. It is suggested that structurally variant glycopeptidolipids of \underline{M} . fortuitum hold tremendous promise in identifying the precise bacterial species for proper chemotherapy of disease. We detail, herein, an elegant protocol to synthesise the complete glycotetrapeptide core of \underline{M} . fortuitum glycopeptidolipid. The peptide bond between \underline{D} -allo-threonine and \underline{D} -alanine was readily identifiable bond disconnection point leading to two glycopeptide halves 2 and 3 whose synthesis were first proposed. The critical \underline{O} -glycosylation processes were performed by employing Schmidt's trichloroacetimidate approach providing a high degree of α -selectivity as glycosyl donors used in this synthetic protocol contained the participating acetyl group at C-2.

L-Rhamnose tetraacetate 4 was selectively deblocked at the anomeric center by using Bu₃SnOEt in refluxing CICH₂CH₂Cl to give 5 which was converted into the trichloroacetimidate derivative 6 with Cl₃CCN-DBU in CH₂Cl₂. Condensation of 6 with N-Cbz-L-alanilol in the presence of BF₃:OEt₂ (catalyst) in CH₂Cl₂ at -20° led to the formation of 7 (70%) which was completely deacetylated under Zemplen condition to obtain 8. The cis 2,3-diol segment of 8 was protected as an acetonide with MeCOMe-Me₂C(OMe)₂-CuSO₄ and then the remaining OH group at C-4 was functionalised as methyl ether (9) with NaH-MeI in THF. After cleavage of the acetonide group with an acid, the product was transformed into the dibutylstannyl acetal derivative (10) by employing Bu₃SnO in refluxing benzene. Treatment of 10 with MeI-Bu₄NI in the same solvent selectively blocked HO-3 to give 11 whose condensation with 2-O-acetyl-3,4-di-O-methyl-L-rhamnopyranose-1-trichloroacetimidate with .BF₃:OEt₂ as catalyst

Scheme - 1

(a) (i) Bu_3^2SnOEt , $CICH_2CH_2CI$, Δ , 3h; (ii) CI_3CCN , CH_2CI_2 , RT, 10 min; (b) (i) \underline{N} -Cbz-L-alanilol, $BF_3^2OEt_2$, CH_2CI_2 , -20° , 0.5h; (ii) NaOMe, MeOH, RT, 1h; (c) (i) MeCOMe, $Me_2C(OMe)_2$, $CuSO_4$, RT, 12h; (ii) NaH, MeI, THF, RT, 3h; (d) (i) 6N HCI, RT, 3h; (ii) Bu_2SnO , C_6H_6 , Δ , 4h; (e) MeI, Bu_4NI , C_6H_6 , Δ , 6h; (f) (i) 3,4- $(OMe)_2$ -2-O-Ac-L-RhaP-1-trichloroacetimidate, $BF_3^2OEt_2$, CH_2CI_2 , -20° , 0.5h; (ii) NaOMe, MeOH, RT, 1h; (g) (i) H_2 , Pd-C, MeOH, RT, 1 atm, 3h; (ii) \underline{N} -Cbz-D-alanine, DCC, HOBt, CH_2CI_2 , RT, 3h; (iii) H_2 , Pd-C, MeOH, RT, 1 atm, 3h.

gave 12. The acetyl group from 12 was removed to give 13 while subsequent hydrogenolysis generated the free amine which was then coupled with $\underline{\text{N-Cbz}D\text{-}alanine}$ in the presence of DCC-HOBt in CH_2Cl_2 at room temperature to provide 14. Finally 14 was hydrogenated over Pd-C in MeOH at normal temperature and pressure to afford 2.

To prepare the second glycopeptide segment 3, the synthesis of the requisite glycosylating donor 19 was first considered from the known 10 starting material 15. Thus, removal

Scheme - 2

(a) (i) $6N^{\circ}$ HCl, RT, 3h; (ii) Bu_3SnO , C_6H_6 , Δ , 3h; (iii) MeI, Bu_4NI , C_6H_6 , Δ , 6h; (b) (i) 3N H_2SO_4 , dioxane, Δ , 6h; (ii) Ac_2O , Py, DMAP, RT, 1h; (iii) Bu_3SnOEt , $CICH_2CH_2CI,\Delta$, 3h; (iv) CI_3CCN , DBU, CH_2CI_2 , RT, 10 min; (c) (i) $BF_3:OEt_2$, CH_2CI_2 , -20° , 0.5h; (ii) H_2 , Pd-C, MeOH, RT, 1 atm, 6h; (d) DCC, HOBt, CH_3CN , RT, 1h.

of the acetonide group from 15 with 6N HCl in THF was followed by selectively protecting 3-OH <u>via</u> the corresponding dibutylstannyl acetal gave 16. Hydrolysis of the methyl glycoside with 3N H_2SO_4 in refluxing dioxane and acetylation gave the diacetate 17. Successive deacetylation at C-1 with Bu_3SnOEt and formation of trichloroacetimidate derivative as described before afforded 19. Due to susceptibility of threonine to undergo elimination of water, we envisaged that the forthcoming O-glycosylation reaction had to be performed with care and thus found that the Schmidt's approach by par most suitable for this endeavour. The dipeptide (20), earlier reported from our Laboratory, was condensed with 19 in the presence of $BF_3:OEt_2$ at -20° to afford 21 (65%). The absolute stereochemistry at the new anomeric center was confirmed to the partially decoupled ^{13}C -NMR spectrum in which the large coupling constant ($_{1}C_{-1}$ ', $_{1}H_{-1}$ ') 170 Hz) indicated $_{1}C_{-1}$ -NMR spectrum in which the large coupling constant ($_{1}C_{-1}$ ', $_{1}H_{-1}$ ') 170 Hz) indicated $_{2}C_{-1}$ -Configuration. Subsequent hydrogenolysis of 21 removed both the benzyl groups giving the required product 3. Finally the two glycopeptides 2 and 3 were subjected to the peptide bond formation in the presence of DCC-HOBT in CH₃CN to give the glycotetrapeptide derivatives (22) (60%).

The epitopes in C-mycoside so far being assumed to be the oligosaccharides attached to the 6-deoxy-L-talose. However, the absence of 6-deoxy-L-talose or its oligosaccharide analogues from M. fortuitum glycopeptidolipid has posed the question of new identification of antigenic determinants. The present results revealing the synthesis of a complex glycotetrapeptide core of M. fortuitum become significant in addressing this issue.

References

- R. J. Wallace, J. M. Musser, S. I. Hull, V. A. Silcox, L. C. Steele, G. D. Forrester, A. Labide, R. K. Selander, J. Infect. Dis., 1989, 159, 708.
- 2. R. C. Good, Annu. Rev. Microbiol., 1985, 39, 347.
- a) P. J. Brennan, Microbial. Lipids, 1988, Academic Press, London, Vol. 1, pp. 203;
 b) P. J. Brennan, The Mycobacteria: A Source Book, Marcel Dekker, New York, Part A, pp 467 (1984);
 c) M. McNeil, D. Chatterjee, S. W. Hunter, P. J. Brennan, Methods Enzymol., (1979).
- 4. L. M. Lopez Martin, M. A. Laneelle, D. Prone, M. Daffe, G. Laneelle, J- C. Prone, Biochemistry, 1991, 30, 10536.
- 5. H. Kunz, Angew. Chem. Int. Ed. Engl., 1987, 26, 294.
- a) M. K. Gurjar, U. K. Saha, <u>Tetrahedron Lett.</u>, 1991, 32, 6621; b) M. K. Gurjar, U. K. Saha, <u>Tetrahedron</u>, 1992, 48, 4039; c) M. K. Gurjar, U. K. Saha, <u>Tetrahedron Lett.</u>, 1992, 34, 4979.
- 7. R. R. Schmidt, Angew. Chem. Int. Ed. Engl., 1986, 25, 212.
- 8. A. Nudelman, J. Harzig, H. E. Gottlieb, Carbohydr. Res., 1987, 162, 145.
- 9. S. David, S. Hannessian, <u>Tetrahedron</u>, 1985, <u>41</u>, 643.
- 10. A. H. Haines, Carbohydr. Res., 1969, 10, 466.
- 11. V. Pozsgay, A. Neszmelyi, Carbohydr. Res. 1980, 80, 196.

- 12. Some physical data of compounds 9, 14, 21, 22:
 - 9 ¹H-NMR data (CDCl₃, 200 MHz) δ 1.12 (d, 3H, <u>J</u>=6.75 Hz, CH₃), 1.27 (d, 3H, <u>J</u>=6.5 Hz, CH₃), 1.35, 1.56 (2s, 6H, (CH₃)₂C), 2.83 (s, 2H), 2.95 (m, 1H), 3.41 (m, 1H), 3.54 (s, 3H, OMe), 4.06 (m, 2H), 4.47 (bs, 1H), 4.95 (s, 1H, H-1'), 5.15 (s, 2H, PhCH₂), 7.35 (s, 5H, Ph).
 - 14 1 H-NMR data (CDCl₃, 200 MHz): δ 1.1-1.4 (m, 12H, 4xCH₃), 3.04 (t, 2H, $\underline{\text{J}}$ =9.0 Hz, H-4',H-4"), 3.38, 3.43 (2s, 6H, 2xOMe), 3.52 (s, 6H, 2xOMe), 3.97 (t, 1H, $\underline{\text{J}}$ =1.0 Hz), 4.15 (m, 2H), 4.72 (d, 1H, $\underline{\text{J}}$ =1.0 Hz, H-1'), 5.04 (d, 1H, $\underline{\text{J}}$ =1.0 Hz, H-1"), 5.13 (s, 2H, PhCH₂), 5.75 (d, 1H, $\underline{\text{J}}$ =8.0 Hz, NH), 6.38 (d, 1H, $\underline{\text{J}}$ =8.0 Hz, NH), 7.35 (s, 5H, Ph); $[\alpha]_{D}$ -30° ($\underline{\text{C}}$ 1, CHCl₃).
 - 21 1 H-NMR data (CDCl $_{3}$, 200 MHz): δ 0.96 (d, 1H, \underline{J} =6.0 Hz, CH $_{3}$), 1.14 (d, 1H, \underline{J} =6.0 Hz, CH $_{3}$), 1.88 (s, 3H, N-Ac), 2.14 (s, 3H, OAc), 3.06 (m, 2H), 3.28 (dd, 2H, \underline{J} =10.0, 18.0 Hz), 3.40 (s, 3H, OMe), 4.3 (m, 1H), 4.58, 4.91 (ABq, 2H, PhC \underline{H}_{2}), 4.68 (d, 1H, \underline{J} =1.0 Hz, H-1'), 4.83 (dd, 1H, \underline{J} =8.0, 14.0 Hz), 5.06 (ABq, 2H, PhC \underline{H}_{2}), 5.14 (m, 1H, H-2'), 6.02 (d, 1H, \underline{J} =8.0 Hz, NH), 6.66 (d, 1H, \underline{J} =9.0 Hz, NH), 7.3 (m, 15H, 3xPh); 13 C-NMR: 6 C- $_{1}$ 93.78 (\underline{J} =170 Hz); [6] $_{0}$ -2° (\underline{c} 1, CHCl $_{3}$).
 - 22 ¹H-NMR data (CDCl₃): δ 0.70 (d, 3H, \underline{J} =6.25 Hz, CH₃), 1.14 (d, 3H, \underline{J} =6.25 Hz, CH₃), 1.29 (m, 9H, 3xCH₃), 1.37 (d, 3H, \underline{J} =6.5 Hz, CH₃), 1.97 (s, 3H, NHAc), 2.12 (s, 3H, OAc), 2.54 (bs, OH), 3.08 (m, 6H), 3.43 (s, 3H, OMe), 3.48 (s, 9H, 3xOMe), 3.52 (s, 3H, OMe), 4.66 (d, 1H, \underline{J} =1.0 Hz, H-1'), 4.72 (d, 1H, \underline{J} =1.0 Hz, H-1"), 5.04 (d, 1H, \underline{J} =1.0 Hz, H-1"), 5.14 (bs, 1H, H-2), 6.20 (d, 1H, \underline{J} =6.2 Hz, NH), 6.64 (t, 2H, \underline{J} =8.7 Hz, 2xNH), 7.30 (m, 5H, Ph), 7.39 (d, 1H, \underline{J} =7.5 Hz, NH); [α] -43° (\underline{c} 0.8, CHCl₃).

IICT Communication No. 3096